Download PDF
Thromb Haemost 1976; 36(03): 634-640
DOI: 10.1055/s-0038-1648084
Original Article
Schattauer GmbH

Impairment of ADP-Induced Platelet Aggregation by Hashish Components

Rachel Levy
1   Biology Department and Research and Development Authority, Ben-Gurion University of the Negev and Blood Research Laboratory, Soroka Medical Center, Beer-Sheva, Israel
,
Avital Schurr
1   Biology Department and Research and Development Authority, Ben-Gurion University of the Negev and Blood Research Laboratory, Soroka Medical Center, Beer-Sheva, Israel
,
Ilana Nathan
1   Biology Department and Research and Development Authority, Ben-Gurion University of the Negev and Blood Research Laboratory, Soroka Medical Center, Beer-Sheva, Israel
,
Alexander Dvilanski
1   Biology Department and Research and Development Authority, Ben-Gurion University of the Negev and Blood Research Laboratory, Soroka Medical Center, Beer-Sheva, Israel
,
Avinoam Livne
1   Biology Department and Research and Development Authority, Ben-Gurion University of the Negev and Blood Research Laboratory, Soroka Medical Center, Beer-Sheva, Israel
› Author Affiliations
Further Information

Publication History

Received 30 August 1975

Accepted 20 July 1976

Publication Date:
03 July 2018 (online)

    Permissions and Reprints

Summary

ADP-induced aggregation of washed human platelets is inhibited by the hashish components Δ1-tetrahydrocannabinol (THC) and cannabidiol (CBD). The inhibition is counteracted by added ADP. When the cannabinoids are present at concentrations higher than 10−5M, the platelets aggregate non-reversibly, independently of an added inducer, apparently due to lysis and release of endogenous inducers. THC is clearly more potent than CBD in exhibiting the biphasic effect. Collagen- and thrombin-induced aggregation of washed platelets are hardly affected by the cannabinoids. THC and CBD also curtail ADP-induced reversible aggregation in platelet-rich plasma, while serotonin release and irreversible aggregation, caused by either ADP, collagen or thrombin, are not affected by the cannabinoids in platelet-rich plasma. The data point to associated sites for ADP and the cannabinoids on the platelet membrane.

 

  • References

  • 1 Ahtee L. 1966; 5-Hydroxytryptamine release from blood platelets and haemolysis of red blood cells of rabbit induced by phenothiazine and related compounds. Annals Medicine Experimentalis et Biologioe Fenniae 44: 453.
    PubMedGoogle Scholar
  • 2 Aledort L. M, Niemtz J. 1968; Dissociation of platelet aggregation from clot retraction, potassium loss and adenosine triphosphatase activity. Proceedings of the Society for Experimental Biology and Medicine 128: 658.
    PubMedGoogle Scholar
  • 3 Alhanaty E, Livne A. 1974; Osmotic fragility of liposomes as affected by antihemolytic compounds. Biochemica et Biophysica Acta 339: 146.
    CrossrefPubMedGoogle Scholar
  • 4 Bino T, Chari-Bitron A, Shahar A. 1972; Biochemical effects and morphological changes in rat liver mitochondria exposed to Δ1-tetrahydrocannabinol. Biochimica et Biophysica Acta 288: 195.
    CrossrefPubMedGoogle Scholar
  • 5 Biran H, Dvilansky A, Nathan I, Livne A. 1973; Impairement of human platelet aggregation and serotonin release caused in vitro by Echis Colorata venom. Thrombosis et Diathesis Haemorrhagica 30: 191.
    PubMedGoogle Scholar
  • 6 Chari-Bitron A, Bino T. 1971; Effect of Δ1-tetrahydrocannabinol on ATPase activity of rat liver mitochondria. Biochemical Pharmacology 20: 473.
    CrossrefPubMedGoogle Scholar
  • 7 Cross M. J. 1964; Effect of fibrinogen on the aggregation of platelets by adenosine diphosphate. Thrombosis et Diathesis Haemorrhagica 12: 524.
    PubMedGoogle Scholar
  • 8 Davey M. G, Lüscher E. F. 1968; Release reactions of human platelets induced by thrombin and other agents. Biochimica et Biophysica Acta 165: 490.
    CrossrefPubMedGoogle Scholar
  • 9 Edery H, Grunfeld Y, Ben-Zvi Mechoulam R. 1971; Structural requirements for cannabinoid activity. Annals of the New York Academy of Sciences 191: 40.
    CrossrefPubMedGoogle Scholar
  • 10 Fehr K. O, Kalant H. 1974; Fate of 14C-Δ1-THC in rat plasma after intravenous injection and smoking. European Journal of Pharmacology 25: 1.
    CrossrefPubMedGoogle Scholar
  • 11 Fishman W. H. 1965. β-Glucuronidase of enzyme activity. In: Bergmeyer H. U. (ed.) Methods of Enzymatic Analysis. Academic Press; New York: 869.
    Google Scholar
  • 12 Haslam R. J. 1964; Role of adenosine diphosphate in aggregation of human platelets by thrombin and by fatty acids. Nature 202: 765.
    CrossrefPubMedGoogle Scholar
  • 13 Holmsen H, Day H. J. 1968; Thrombin induced platelet release reaction and platelet lysosomes. Nature 219: 760.
    CrossrefPubMedGoogle Scholar
  • 14 King A. B, Cowen D. L. 1964; Effect of intravenous injection of marihuana. Journal of American Medical Association 210: 4.
    PubMedGoogle Scholar
  • 15 King A. B, Pechet G. S, Pechet L. 1970; Intravenous injection of crude marihuana. Journal of American Medical Association 214: 9.
    PubMedGoogle Scholar
  • 16 Levy R, Livne A. 1976; Mode of action of hashish compounds in reducing blood platelet count. Biochemical Pharmacology 25: 359.
    CrossrefPubMedGoogle Scholar
  • 17 Levy R, Friendlander M, Dvilanski A, Livne A. 1975; Effects of the hashish component Δ1-THC on the ultrastructure of human platelets. Israel Journal of Medical Sciences 11: 401 Abstract.
    PubMedGoogle Scholar
  • 18 Mechoulam R, Gaoni Y. 1967; Recent advances in chemistry of hashish. Fortschritte der Chemie Organischer Naturstoffe 25: 175.
    PubMedGoogle Scholar
  • 19 Paton W. D. M, Pertwee R. G, Temple D. 1972. The general pharmacology of cannabinoids. In: Paton W. D. M, Crown J. (eds.) Cannabis and its Derivatives. Oxford University Press; London: 51.
    Google Scholar
  • 20 Pechet L, King A. B, Pechet G. S. 1970; The effect of intravenous marihuana on coagulation, and on platelets and white cell count. Federation Proceedings 29: 441 Abstract.
    PubMedGoogle Scholar
  • 21 Raz A, Schurr A, Livne A. 1972; The interaction of hashish components with human erythrocytes. Biochimica et Biophysica Acta 274: 269.
    CrossrefPubMedGoogle Scholar
  • 22 Raz A, Schurr A, Livne A, Goldman R. 1973; Effect of hashish compounds on rat liver lysosomes in vitro . Biochemical Pharmacology 22: 3129.
    CrossrefPubMedGoogle Scholar
  • 23 Schurr A, Livne A. 1976; Differential inhibition of mitochondrial manoamine oxidase from brain by hashish components. Biochemical Pharmacology 25: 1201.
    CrossrefPubMedGoogle Scholar
  • 24 Schurr A, Sheffer N, Graziani Y, Livne A. 1974; Inhibition of glucose efflux from human erythrocytes by hashish components. Biochemical Pharmacology 23: 2005.
    CrossrefPubMedGoogle Scholar
  • 25 Seeman P. 1972; The membrane actions of anesthetics and tranquilizers. Pharmacological Reviews 24: 583.
    PubMedGoogle Scholar
  • 26 Tekkä A, Nyholm M, Paasonen M. K. 1964; Effect of chloropromazine and reserpine on blood platelets of rabbits. Experientia 20: 27.
    CrossrefPubMedGoogle Scholar
  • 27 Wahlquist M, Nillson I. M, Sandberg F, Agurell S, Granstrand B. 1970; Binding of Δ1-tetrahydrocannabinol to human proteins. Biochemical Pharmacology 19: 2579.
    CrossrefPubMedGoogle Scholar
  • 28 Wessells N. K, Spooner B. S, Ash J. F, Bradley M. O, Ludvena M. A, Tayler E. L, Wrenn J. T, Yanada K. B. 1971; Microfilaments in cellular and developmental processes. Science 171: 135.
    CrossrefPubMedGoogle Scholar
  • 29 White J. G, Krumwiede M. 1973; Influence of cytochalasin B on shape change induced in platelets by cold. Blood 41: 823.
    PubMedGoogle Scholar
  • 30 Wroblewski F, Ladue J. S. 1964. Lactate dehydrogenase activity. In: King E. J. (ed.) Micro-Analyses in Medical Biochemistry. J. A. Churchill; London: 177.
    Google Scholar